Drugs that contain Mometasone Furoate
1. Asmanex Hfa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5889015 | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6365581 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6057307 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
|
US5889015 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6365581 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6057307 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
| US6068832 | ORGANON LLC | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
Aug, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 12, 2022 |
| Pediatric Exclusivity(PED) | Feb 12, 2023 |
Market Authorisation Date: 12 August, 2019
Treatment: Treatment of asthma
Dosage: AEROSOL, METERED;INHALATION
More Information on Dosage
ASMANEX HFA family patents
2. Asmanex Twisthaler patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5394868 (Pediatric) | ORGANON LLC | Inhalation device for powdered medicaments |
Dec, 2012
(11 years ago) | |
| US5889015 | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6057307 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6365581 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6677322 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6949532 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
|
US5889015 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6677322 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6365581 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6057307 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6949532 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
| US5687710 | ORGANON LLC | Inhaler for powdered medications having spiral deagglomeration chamber |
Nov, 2014
(9 years ago) | |
|
US5687710 (Pediatric) | ORGANON LLC | Inhaler for powdered medications having spiral deagglomeration chamber |
May, 2015
(8 years ago) | |
| US5829434 | ORGANON LLC | Inhaler for powdered medications |
Nov, 2015
(8 years ago) | |
|
US5829434 (Pediatric) | ORGANON LLC | Inhaler for powdered medications |
May, 2016
(7 years ago) | |
| US6240918 | ORGANON LLC | Powdered medication inhaler |
Feb, 2017
(7 years ago) | |
|
US6240918 (Pediatric) | ORGANON LLC | Powdered medication inhaler |
Aug, 2017
(6 years ago) | |
| US6503537 | ORGANON LLC | Preparation of powder agglomerates |
Mar, 2018
(6 years ago) | |
| US8173172 | ORGANON LLC | Preparation of powder agglomerates |
Mar, 2018
(6 years ago) | |
|
US8173172 (Pediatric) | ORGANON LLC | Preparation of powder agglomerates |
Sep, 2018
(5 years ago) | |
|
US6503537 (Pediatric) | ORGANON LLC | Preparation of powder agglomerates |
Sep, 2018
(5 years ago) | |
Market Authorisation Date: 01 February, 2008
Treatment: Treatment of asthma
Dosage: POWDER;INHALATION
More Information on Dosage
ASMANEX TWISTHALER family patents
3. Nasonex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6127353 | ORGANON LLC | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
Oct, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6723713 | ORGANON LLC | Use of mometasone furoate for treating upper airway diseases |
Jan, 2014
(10 years ago) | |
| US5837699 | ORGANON LLC | Use of mometasone furoate for treating upper airway passage diseases |
Jan, 2014
(10 years ago) | |
|
US6723713 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating upper airway diseases |
Jul, 2014
(9 years ago) | |
|
US5837699 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating upper airway passage diseases |
Jul, 2014
(9 years ago) | |
|
US6127353 (Pediatric) | ORGANON LLC | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
Apr, 2018
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-99) | Jan 19, 2014 |
| New Indication(I-626) | May 26, 2013 |
Market Authorisation Date: 01 October, 1997
Treatment: Allergic rhinitis or nasal polyps
Dosage: SPRAY, METERED;NASAL
How can I launch a generic of NASONEX before it's drug patent expiration?
More Information on Dosage
NASONEX family patents
4. Sinuva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7951130 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(a month ago) | |
| US7713255 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(a month ago) | |
| US7951133 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(a month ago) | |
| US7662141 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(a month ago) | |
| US8109918 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(a month ago) | |
| US7951131 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(a month ago) | |
| US9585681 | INTERSECT ENT INC | Device and methods for treating paranasal sinus conditions |
Apr, 2026
(1 year, 11 months from now) | |
| US7544192 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Nov, 2026
(2 years from now) | |
| US8025635 | INTERSECT ENT INC | Device and methods for treating paranasal sinus conditions |
Jun, 2027
(3 years from now) | |
| US10357640 | INTERSECT ENT INC | Expandable devices and methods for treating a nasal or sinus condition |
Oct, 2031
(7 years from now) | |
| US8763222 | INTERSECT ENT INC | Methods and devices for crimping self-expanding devices |
Feb, 2032
(7 years from now) | |
| US10406332 | INTERSECT ENT INC | Systems, devices, and method for treating a sinus condition |
Mar, 2034
(9 years from now) | |
| US10232152 | INTERSECT ENT INC | Systems, devices, and method for treating a sinus condition |
Nov, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 08, 2020 |
Market Authorisation Date: 08 December, 2017
Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant
Dosage: IMPLANT;IMPLANTATION
More Information on Dosage
SINUVA family patents